Wednesday, 13 Dec 2017

You are here

Biosimilar Pricing Wars Have Begun

This week Merck announched the US launch of its biosimilar to infliximab, and announced it will discount 35% to the branded version's wholesale acquisition cost. This comes in stark contrast to Pfizer's Inflectra, another infliximab biosimilar, that was lauched with a disappointing 15% discount. Disappointing to those expecting greater savings with biosimilars being newly launched.

Despite the approval of four anti-TNF biosimilars in 12 months, their introduction into the U.S. market has been slow and - until now - with paultry discounts compared to their introduction throughout Europe, where discounts averaged 50% and were as high as 70% (compared to the price of Remicade).

Merck has priced Renflexis at a deeper discount to Remicade (Janssen) and Inflectra (Pfizer). Renflexis will have an introductory wholesale acquisition cost (WAC) of $753.39. The WAC of Remicade was $1,167.82 and Inflectra (infliximab-dyyb) was $946.28 according to Red Book July 24.  WACs do not include discounts that may be paid on the products.

Renflexis was developed by Samsung Bioepis and is being marketed by Merck in the U.S. Renflexis was approved by the FDA on April 21 for the following indications:  Crohn's, pediatric Crohn's disease, rheumatoid arthritis, psorisis, psoriatic arthritis and ankylosing spondylitis.

Sales of Remicade did drop 14% year over year in the second quarter, but J&J chalked much of that decline up to the roughly $170 million in rebate adjustments in the same period last year.

The pricing schemes are unknown for the biosimilars to follow, including Sandoz's Erelzi (etanercept) and Amgen's Amjevita (adalimumab). 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Why TNF Inhibitors May Work in Some Autoinflammatory Patients

The NLRP3 inflammasome is a critical component of the innate immune system and activation of NLRP3 inflammasome results in caspase-1–dependent secretion of the proinflammatory cytokines IL-1β and IL-18. Gain-of-function missense mutations in NLRP3 is thought to drive many of the autoinflammatory diseases, especially the cryopyrin-associated periodic syndromes (CAPS).

Infliximab Does Not Increase Perioperative Infection

Staying on a TNF inhibitor (TNFi) throughout major surgery has generatlly been associated with higher rates of perioperative infection (https://buff.ly/2iBFVjp).  On the other hand, discontinuation of the TNFi prior to surgery is associated with lower rates of  infection (https://buff.ly/2iAFZQf)

CALM Study: Tight Control with Anti-TNF Wins in Crohn's Disease

Not unlike rheumatoid arthritis and other inflammatory disorders, therapeutic efficacy in Crohn's disease (CD) is often assessed clinically. There is growing use and interest in biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein. But Lancet has now reported a clinical trial has shown that a tight control strategy can yield better responses to TNF inhibitors when compared to usual care. 

Amgen-Abbvie Settle Humira Biosimilar Patent Dispute

Amgen's biosimilar version of adalimumab (Humira) was FDA-approved in September 2016 and given the trade name Amjevita (generic: adalimumab-atto). This new TNF inhibitor biosimilar has not yet been to market because of legal wranglings over patent issues by Abbvie's Humira.

Another Adalimumab Biosimilar Approved

On Friday August 25th, the FDA approved another adalimumab biosimilar: Cyltezo (generic name: adalimumab-adbm).